NicOx reacquires rights to PF-03187207 for glaucoma from Pfizer
06-Aug-2009 -
NicOx S.A. announced the signature of an agreement with Pfizer Inc to reacquire the full development and commercialization rights to PF-03187207, which has completed two phase 2 studies in patients with primary open angle glaucoma and ocular hypertension. As part of this agreement, Pfizer has ...
business development
eye disease
glaucoma
+2